Suppr超能文献

80 岁或以上食管癌患者同步放化疗是否有益?

Is Concurrent Chemotherapy With Radiotherapy for Esophageal Cancer Beneficial in Patients Aged 80 Years or Older?

机构信息

Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan

Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.

出版信息

Anticancer Res. 2019 Aug;39(8):4279-4283. doi: 10.21873/anticanres.13592.

Abstract

BACKGROUND/AIM: To determine whether concurrent chemotherapy with radiotherapy should be performed in elderly patients with esophageal cancer.

PATIENTS AND METHODS

A total of 185 patients aged 80 years or older who were treated with definitive radiotherapy alone or combined with chemoradiotherapy for esophageal cancer at seven institutions were enrolled. In order to compare survival rates of patients treated with chemoradiotherapy with those of patients treated with radiotherapy alone, propensity score matching was performed to homogenize the two populations.

RESULTS

For the whole patient cohort, the 3-year overall survival (OS) rate was 52.6% and the median survival was 42.5 months. After propensity score matching, the 3-year OS rate for the chemoradiotherapy group was not significantly better than that for the group treated with radiotherapy alone (53.7% vs. 59.9%, p=0.876).

CONCLUSION

Concurrent chemotherapy with radiotherapy for esophageal cancer in patients aged 80 years or older did not have significant OS benefit over radiotherapy alone.

摘要

背景/目的:确定在老年食管癌患者中是否应同时进行放化疗。

患者和方法

共纳入了 185 名在 7 家机构接受单纯根治性放疗或放化疗联合治疗的 80 岁及以上食管癌患者。为了比较放化疗组和单纯放疗组患者的生存率,采用倾向评分匹配法使两组人群均衡。

结果

对于全患者队列,3 年总生存率(OS)为 52.6%,中位生存时间为 42.5 个月。经过倾向评分匹配后,放化疗组 3 年 OS 率与单纯放疗组相比没有显著改善(53.7% vs. 59.9%,p=0.876)。

结论

对于 80 岁及以上的食管癌患者,与单纯放疗相比,同时进行放化疗并没有显著的 OS 获益。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验